Research and Markets (http://www.researchandmarkets.com/research/ssmzdq/renal_cancer_drug) has announced the addition of the "Renal Cancer Drug Pipeline Update 2015" report to their offering.

The high existing unmet need in the treatment of renal cancer is reflected by the poor prognosis of patients with advanced stage disease, five- year survival rates with existing cytokine therapy being less than 20% (RCC) in this patient cohort.The identification of biomarkers is set to revolutionize patient staging and prognosis by individualizing patient treatments and creating novel drug targets.

There are today 182 companies plus partners developing 211 drugs targeting renal cancer in development. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 95 drugs.

Renal Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 210 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer.

To date 203 out of the 206 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 53 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Pipeline Breakdown According to Number of Drugs

  • Marketed 25
  • Registered 1
  • Pre-registration 1
  • Phase III 12
  • Phase II 79
  • Phase I 67
  • Preclinical 26
  • Suspended 3
  • Ceased 95

For more information visit http://www.researchandmarkets.com/research/ssmzdq/renal_cancer_drug

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: Oncology